Renalytix PLC
LSE:RENX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (26.1), the stock would be worth GBX10.57 (471% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.6 | GBX1.85 |
0%
|
| 3-Year Average | 26.1 | GBX10.57 |
+471%
|
| 5-Year Average | 89.3 | GBX36.13 |
+1 853%
|
| Industry Average | 0 | GBX0 |
-100%
|
| Country Average | 0 | GBX0 |
-100%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
GBX12.4m
|
/ |
Jan 2026
$3.3m
|
= |
|
|
GBX12.4m
|
/ |
Jun 2026
$19m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Renalytix PLC
LSE:RENX
|
8.1m GBP | 4.6 | -0.5 | |
| JP |
|
Medical Data Vision Co Ltd
TSE:3902
|
37.9T JPY | 9.5 | 227.5 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 5.5 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
26.4B USD | 6.2 | 29 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.5B AUD | 57.2 | 61.6 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 2.6 | 20.5 | |
| SE |
|
Sectra AB
STO:SECT B
|
51.8B SEK | 21.6 | 96.4 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.9B USD | 5.6 | 42.4 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.4B USD | 5.8 | 18.6 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
19.3B CNY | 8.8 | -62.7 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 11.4 | -328 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 3 279.7 |
Other Multiples
Renalytix PLC
Glance View
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
